6000 Shoreline Court
South San Francisco
Perlara was originally founded as Perlstein Lab, PBC in February 2014. Perlara, PBC is a biotech startup and Public Benefit Corporation based in the Bay Area that is on a mission to accelerate the discovery of cures for specific diseases and uncover underlying mechanisms that enable the development of treatments that work across a range of diseases and individuals.
Founders: Henry Perlstein and Ethan Perlstein
CEO: Ethan Perlstein, PhD
7 articles with Perlara
APOL1 kidney disease PerlQuest co-development partnership with Rambam Medical Center in Haifa, Israel, and the laboratory of leading nephrologist and kidney disease researcher Dr. Karl Skorecki.
Radical Investments is the venture capital firm of serial entrepreneur and impact investor Mark Cuban.
Perlara today announced a Mucopolysaccharidosis Type IIIA and Type IIIB PerlQuest partnership with Cure Sanfilippo Foundation, a South Carolina-based 501(c)(3) not-for-profit organization funding research to develop treatments and a cure for Sanfilippo Syndrome.
Glycogen storage diseases (GSD) are monogenic recessive inborn errors in metabolism involving genes that synthesize or degrade glycogen in cells and tissues of the body.
Multiple Sulfatase Deficiency is an ultra-rare monogenic lysosomal disorder caused by mutations in the evolutionarily conserved gene SUMF1
Perlara, a drug discovery platform company partnering with highly motivated families and drug developers to treat diseases thought too rare to attract the interest of pharmaceutical companies, today announced a collaboration with Harvard Medical School and the Undiagnosed Diseases Network to launch PerlQuests for two rare monogenic neurodevelopmental disorders.
Perlstein's approach with his start-up, Perlara, is radically different from how most start-ups operate.